Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.
Press releases published on May 27, 2025
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire
·
May 27, 2025
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 …
Regula Rolls Out Personal Data Masking Across All Solutions for Easier Privacy Compliance
GlobeNewswire
·
May 27, 2025
RESTON, Va., May 27, 2025 (GLOBE NEWSWIRE) -- To help organizations stay ahead of tightening data privacy regulations, Regula, a global developer of identity verification solutions, has extended its personal data masking functionality to Regula Forensic …
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced a strategic collaboration to …
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report
GlobeNewswire
·
May 27, 2025
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related …
Canstar Ramps Up Critical Minerals Exploration With Initial Payment from $11.5M Strategic Exploration JV
GlobeNewswire
·
May 27, 2025
TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- (TSXV: ROX) (OTCPK: CSRNF) Canstar Resources Inc. is ramping up critical metals exploration in Newfoundland with the receipt of the initial $500,000 tranche of its previously announced $11.5M strategic exploration …
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
GlobeNewswire
·
May 27, 2025
MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) …
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2…
GlobeNewswire
·
May 27, 2025
CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal antibody or vaccine with placebo-controlled clinical …
BioCryst to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Jefferies Global Healthcare Conference in New York on Wednesday, …
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual …
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
GlobeNewswire
·
May 27, 2025
NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Nasdaq Hearings Panel …
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase …
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer
GlobeNewswire
·
May 27, 2025
Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise as Leader of Lifecore’s Sales Organization Focused on …
Xtract One Teams Up with MLB’s Colorado Rockies to Deploy SmartGateway at Coors Field, Bringing Frictionless Screening to Fans this Season
GlobeNewswire
·
May 27, 2025
TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced it has signed an agreement with the Colorado Rockies (“Rockies”) of Major League Baseball (MLB) to use …
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
GlobeNewswire
·
May 27, 2025
Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the …
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or …
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
GlobeNewswire
·
May 27, 2025
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest – – LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q …
NewGen Announces Strategic Expansion with Services Tailored for Indian Medical Tourists
GlobeNewswire
·
May 27, 2025
BANGKOK, May 27, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that …
Castellum, Inc. Announces Information Concerning 2025 Annual Stockholders Meeting
GlobeNewswire
·
May 27, 2025
VIENNA, Va., May 27, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM) ("Castellum" or "CTM"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, reminds stockholders that its 2025 …
Brazil Potash Announces Launch of Brazilian Depositary Receipts (BDRs) on B3 Exchange
GlobeNewswire
·
May 27, 2025
BDRs will provide Brazilian investors direct access to invest in the largest domestic potash development project Strategic step to expand investor base in Brazil, aligning with National Fertilizer Plan's goal of reducing import dependence Trading on B3 …
Brazil Potash Anuncia Lançamento de Brazilian Depositary Receipts (BDRs) na Bolsa B3
GlobeNewswire
·
May 27, 2025
Os BDRs proporcionarão aos investidores brasileiros acesso direto para investir no maior projeto de desenvolvimento de potássio do país Etapa estratégica para expandir a base de investidores no Brasil, alinhando-se ao objetivo do Plano Nacional de …